The specialist cancer drug discovery and development business has conducted a successful fundraising of £681k at 0.4p. The recently appointed Non-executive Director Clive Birch subscribed for 1.25m shares at the placing price. The net proceeds will be used to progress the Company's TYK2/JAK1 drug development programmes as well as for working capital purposes.
